Table of contents
- Overview of Rosuvastatin trials
- Conditions being studied
- Trial design, phases, and who can join
- Main outcomes and endpoints
- What Rosuvastatin is compared with
- Notable trial examples
- What these studies mean for patients
Overview of Rosuvastatin trials
The trial data show Rosuvastatin being studied in many different settings, mostly for people with high cardiovascular risk or cholesterol-related disease.[1][2]
Most studies are Phase 3 trials, which usually means they are testing how well a treatment works in larger groups of patients.[1][4]
There is also a small Phase 1 bioequivalence study in healthy volunteers and a Phase 4 imaging study in people with coronary artery disease and stable chest pain.[6][7]
Conditions being studied
Rosuvastatin is being tested in people with covert brain infarction, dyslipidaemia, hyperlipidemia, hypercholesterolemia, and atherosclerotic cardiovascular disease.[1][2][3][10]
Some trials focus on people after ischemic stroke or transient ischemic attack, while others study people with coronary artery disease, stable chest pain, or non-obstructive coronary artery disease.[5][7][8]
One study includes children with heterozygous familial hypercholesterolemia, which is an inherited form of high cholesterol.[8]
Another study looks at people with a high polygenic risk for coronary artery disease, meaning their risk is linked to many small genetic factors.[4]
Trial design, phases, and who can join
The studies are interventional, which means participants receive a treatment and the researchers measure the results.[1][2]
Several trials are pragmatic or comparative studies, meaning they are designed to test treatment choices in real clinical practice or against another active treatment.[1][3][8]
Some studies include older adults, such as frail people aged 70 and above with recent ischemic stroke or TIA.[5]
Other studies include healthy volunteers, adults with high cholesterol, or children with familial hypercholesterolemia.[6][8][10]
Main outcomes and endpoints
Many Rosuvastatin trials measure LDL-C, which is the main form of bad cholesterol and a common treatment goal.[3][8][11]
Other studies measure serious clinical events, such as MACE, MACCE, cardiovascular death, stroke, heart attack, or revascularization, which means a procedure to open blocked blood vessels.[1][4][5][10]
Some trials focus on safety, including fatal or major bleeding, or on muscle-related side effects detected through symptoms and blood tests.[1][9]
Other endpoints include plaque volume in the coronary arteries, health-related quality of life, hormone levels, and bioequivalence measures such as AUC and Cmax, which describe how much medicine enters the body and the highest level reached in blood.[2][5][6][7]
What Rosuvastatin is compared with
Several trials compare Rosuvastatin-based treatment with other statins such as atorvastatin, pravastatin, fluvastatin, simvastatin, or combination therapy with ezetimibe or fenofibrate.[3][5][8][9][11]
Some studies also compare Rosuvastatin treatment with placebo, especially when the main question is whether adding another medicine changes cholesterol levels or artery plaque progression.[7][10][11]
In a few trials, Rosuvastatin is part of a larger treatment plan alongside newer lipid-lowering medicines such as inclisiran or alirocumab.[8][10][11]
Notable trial examples
The covert brain infarction trial is a large Phase 3 study with 1202 participants, looking at whether antiplatelet and/or statin treatment adds long-term benefit for reducing vascular events and death, while also checking the risk of major bleeding.[1]
The LEASH study compares high-intensity Rosuvastatin or Rosuvastatin/ezetimibe with the goal of helping high and very high risk patients reach LDL-C targets after 12 weeks.[9]
The PICOLO-FH trial studies children with heterozygous familial hypercholesterolemia and measures whether treatment strategies can help them reach LDL-C below 100 mg/dL after 104 weeks.[8]
The V-PLAQUE study uses coronary CT imaging to see whether adding inclisiran on top of statin therapy can reduce total coronary atheroma volume over 24 months in people with non-obstructive coronary artery disease.[7]
The bioequivalence study in healthy volunteers compares two rosuvastatin/ezetimibe formulations and measures blood exposure levels to show that the test product performs like the reference product.[6]
What these studies mean for patients
These trials show that Rosuvastatin is being studied across a wide range of patient groups, from people with inherited high cholesterol to older adults after stroke and people with known heart disease.[4][5][8][10]
The main research questions are whether Rosuvastatin-based treatment can lower LDL-C, prevent serious heart and brain events, and improve overall outcomes in daily life.[1][3][5]
Because the studies use different designs and comparison groups, they help researchers understand where Rosuvastatin fits best in prevention and treatment plans for cardiovascular disease.[2][7][11]
